NEW PRAGUE, Minn. / Aug 07, 2024 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the Canaccord Genuity 44th Annual Global Growth Conference being held in Boston on August 13-15, 2024.
Electromed’s management team will present at 2:30 p.m. Eastern Time on Wednesday, August 14, 2024. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations. You can also access the live webcast here.
In advance of the event, Electromed has published an updated investor presentation deck for review by interested parties. The updated presentation can be found on the Electromed website at Events & Presentations or on the SEC website at www.sec.gov.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Last Trade: | US$22.27 |
Daily Change: | 0.04 0.18 |
Daily Volume: | 41,581 |
Market Cap: | US$188.400M |
April 03, 2025 November 12, 2024 October 28, 2024 August 27, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load